Over 35 million people worldwide are currently infected by HIV. Antiviral therapies can keep the virus from multiplying. However, no drug can cure infection so far, because various cell types continue to carry the virus in a latent, i.e. quiescent, state. Scientists of Helmholtz Zentrum München have now established a model for latent HIV infection of brain cells. The researchers used this model to identify various compounds that affect latency of the virus in the brain. This study was published in the journal AIDS.
“Chronic infection is caused by long-lived cells with resting viral genomes that are activated by different factors,” explained Prof. Dr. Ruth Brack-Werner of the Institute of Virology. “These so-called latently infected cells occur in the blood and in the brain, among others.
Picture: Prof. Dr. Ruth Brack-Werner and Dr. Martha Schneider
HIV latency in the brain is particularly difficult to investigate,” she added. Her research group is studying HIV persistence in a very important type of brain cells called astrocytes. The human brain contains billions of them. The many functions of astrocytes include protecting the brain from injury and harmful agents and providing essential support for nerve cells. Mature astrocytes can have a very long lifespan and may exist for years.
Recent studies identified HIV genomes in up to 19% of astrocytes in brain tissues from deceased HIV-1 infected individuals. So far, no experimental model has existed to study HIV latency in these cells. “With our model system, we can simulate latent HIV infection in astrocytes,” said Dr. Martha Schneider, first author of the study.
The researchers showed that various substances, including the cytokine TNF-alpha, can reactivate the inactive virus. Conversely, it was also possible to inhibit the reactivation of the virus by treating the cells with certain compounds. “These results identify drug candidates that may prevent activation of latent viruses in astrocytes”, Schneider concluded.
In the future, the scientists plan to use this system to study the effect of these and other compounds that may prevent the activation of HIV-1 in the brain. As study director Brack-Werner explained: “Several viral proteins are toxic to neurons and may cause immune damage in the brain. Since only limited replacement of astrocytes occurs in the brain, loss of these cells may cause serious damage. Thus silencing the virus in brain cells is an important goal.” In addition, the researchers plan to test the effect of approved drugs and thus to improve the clinical care of HIV-1 patients in the future.
Schneider, M. et al. (2015). A new model for post-integration latency in macroglial cells to study HIV-1 reservoirs of the brain, AIDS, DOI:10.1097/QAD.0000000000000691
As German Research Center for Environmental Health, Helmholtz Zentrum München pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes mellitus and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München has about 2,300 staff members and is headquartered in Neuherberg in the north of Munich. Helmholtz Zentrum München is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members.
The Institute of Virology (VIRO) investigates viruses that chronically infect humans and can cause life-threatening diseases. The research activities of the institute focus mainly on the HI virus which causes AIDS, on endogenous retroviruses, which are integrated into our germline, and hepatitis B and C viruses, which cause liver cirrhosis and hepatocellular carcinoma. Molecular studies identify new diagnostic and therapeutic concepts to prevent and treat these viral diseases or to prevent the formation of virus-induced tumors.
Contact for the media:
Department of Communication, Helmholtz Zentrum München – German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg - Phone: +49-(0)89-3187-2238 - Fax: +49 89-3187-3324 - Email: firstname.lastname@example.org
Scientific contact at Helmholtz Zentrum München:
Prof. Dr. Ruth Brack-Werner, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Institut für Virologie, Ingolstädter Landstr. 1, 85764 Neuherberg – Phone: +49-(0)89-3187-2923 - Email: email@example.com
http://www.helmholtz-muenchen.de/en/index.html - Website Helmholtz Zentrum München
http://www.helmholtz-muenchen.de/en/viro/index.html - Website Institute of Virology
http://www.helmholtz-muenchen.de/aktuelles/pressemitteilungen/2015/index.html - Press Releases of the Helmholtz Zentrum München
Kommunikation | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences